False-positive cardiac troponin I results can occur due to heterophilic antibodies, highlighting the critical need to evaluate cardiac markers in concert with clinical data.
Answers are grounded in this paper and cite their sources.
Integrate cTnI with clinical context to avoid interference misdiagnosis; case reports leave open prevalence and systematic testing needs.
Cardiac markers are important in the diagnosis of acute myocardial infarction, especially in patients with an equivocal electrocardiogram pattern. Recently, cardiac troponin I (cTnI) immunoassays have been used to diagnose myocardial infarction, because of this marker’s specificity, sensitivity, and duration of elevated values. Immunoassays are the standard for analysis of cTnI and other cardiac markers. This report documents two cases in which cTnI values were discrepant with the clinical diagnosis. Retrospective analysis identified heterophilic antibodies as responsible for the discrepancies in one and possibly both cases. These cases expound the limitations of immunoassays and illustrate that cardiac markers must always be evaluated in concert with clinical data.
No takes yet. Share an insight, caveat, or question.
Volk et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: